Financial Survey: Neuphoria Therapeutics (NASDAQ:NEUP) vs. Upstream Bio (NASDAQ:UPB)

Neuphoria Therapeutics (NASDAQ:NEUP) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Neuphoria Therapeutics and Upstream Bio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1	2	0	0	1.67
Upstream Bio	1	2	4	0	2.43

Neuphoria Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 128.76%. Upstream Bio has a consensus price target of $29.67, suggesting a potential upside of 807.24%. Given Upstream Bio’s stronger consensus rating and higher probable upside, analysts plainly believe Upstream Bio is more favorable than Neuphoria Therapeutics.

Insider & Institutional Ownership

15.9% of Neuphoria Therapeutics shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by company insiders. Comparatively, 16.5% of Upstream Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Neuphoria Therapeutics and Upstream Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-38.31%	-28.92%
Upstream Bio	-4,955.67%	-48.40%	-46.57%

Risk and Volatility

Neuphoria Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Upstream Bio has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.

Valuation and Earnings

This table compares Neuphoria Therapeutics and Upstream Bio”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$1.17 million	14.15	-$13.45 million	($6.22)	-0.49
Upstream Bio	$2.85 million	62.84	-$143.44 million	($2.90)	-1.13

Neuphoria Therapeutics has higher earnings, but lower revenue than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Upstream Bio beats Neuphoria Therapeutics on 8 of the 13 factors compared between the two stocks.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

About Upstream Bio

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.